Match tier
Listed
Presence
Current · Arkansas
Last published
2025
Sources
OpenAlex · ORCID
Refreshed
2026-08-08
M
Maha Hanafi
Researcher
Also affiliated: Cairo University (2018–2025); University of Michigan (2018–2025); Misr International University (2018)
Unknown Researcher
3 h-index
5 pubs
92 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Maha Hanafi's research focuses on the discovery and development of novel therapeutic agents, with a significant emphasis on pancreatic cancer. Her work has involved the design and synthesis of various small molecules, including quinolyl pyrazinamides as sigma 2 receptor ligands and pyrazolo[3,4-d]pyrimidine derivatives as BRK/PTK6 inhibitors. She has also investigated napabucasin PROTACs for E3 ligase degradation and dual RET/TRKA inhibitors based on 9H-pyrimido[4,5-b]indole scaffolds.
Hanafi's recent publications explore the therapeutic vulnerability of the copper-KRAS-COX2 axis in pancreatic cancer and the development of DNA-PKcs inhibitors with improved solubility. Her research also extends to understanding kinase inhibitor macrocycles and their conformational flexibility. She collaborates with researchers at the University of Arkansas for Medical Sciences, including Brendan Frett and Baku Acharya. Hanafi has published 5 papers, accumulating 90 citations, and holds an h-index of 3.
Metrics
- h-index: 3
- Publications: 5
- Citations: 92
Selected Publications
-
Discovery of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRK/PTK6 inhibitors (2025)
-
Discovery of Novel 1h-Pyrazolo[3,4-D]Pyrimidine Derivatives as Brk/Ptk6 Inhibitors (2025)
-
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present) (2025)
-
Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441 (2024)
-
Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors (2024)
-
Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules (2023)
Collaboration Network
Top Collaborators
Daniel W. Armstrong
University of Arkansas for Medical Sciences
5 shared publications
In database
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
- An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present)
- Discovery of Novel 1h-Pyrazolo[3,4-D]Pyrimidine Derivatives as Brk/Ptk6 Inhibitors
Brendan Frett
University of Arkansas for Medical Sciences
5 shared publications
In database
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
- An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present)
- Discovery of Novel 1h-Pyrazolo[3,4-D]Pyrimidine Derivatives as Brk/Ptk6 Inhibitors
Baku Acharya
University of Arkansas for Medical Sciences
4 shared publications
In database
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
- Discovery of Novel 1h-Pyrazolo[3,4-D]Pyrimidine Derivatives as Brk/Ptk6 Inhibitors
Debasmita Saha
University of Arkansas for Medical Sciences (US)
3 shared publications
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- Discovery of Novel 1h-Pyrazolo[3,4-D]Pyrimidine Derivatives as Brk/Ptk6 Inhibitors
Baha’a Jabali
University of Arkansas for Medical Sciences
2 shared publications
In database
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
Alan Herrera-Rueda
University of Arkansas for Medical Sciences
1 shared publication
In database
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
Naga Rajiv Lakkaniga
Indian Institute of Technology Dhanbad (IN)
1 shared publication
- Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules
Noemi Garcia Garcia
University of Arkansas for Medical Sciences
1 shared publication
In database
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
Katie R. Ryan
University of Arkansas for Medical Sciences
1 shared publication
In database
- Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
Zachary J. Waldrip
Arkansas Children's Hospital
1 shared publication
In database
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
Randall R Rainwater
Arkansas Children's Hospital
1 shared publication
In database
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
Sharon Amole
University of Arkansas for Medical Sciences
1 shared publication
In database
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
Madeline Fulmer
University of Arkansas for Medical Sciences
1 shared publication
In database
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
Ana Clara P. Azevedo‐Pouly
Arkansas Children's Hospital
1 shared publication
In database
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
Alaina Burns
University of Arkansas for Medical Sciences
1 shared publication
In database
- Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441
Similar Researchers
Based on overlapping research topics
Hong-yu Li
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Structure-Activity Relationship
Drug Transport and Resistance Mechanisms
Amal Shoeib
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Structure-Activity Relationship
Drug Transport and Resistance Mechanisms
Mattie R Nester
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Drug Transport and Resistance Mechanisms
Receptor Mechanisms and Signaling
Priya Yadav
University of Arkansas at Pine Bluff
Cancer Treatment and Pharmacology
Drug Transport and Resistance Mechanisms
Receptor Mechanisms and Signaling
Anna Radomińska‐Pandya
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Drug Transport and Resistance Mechanisms
Receptor Mechanisms and Signaling
Delgado-Calle Jesus
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Drug Transport and Resistance Mechanisms
Receptor Mechanisms and Signaling